BTIG analyst Thomas Shrader lowered the price target on Gain Therapeutics (NASDAQ: GANX) to $9.00 (from $10.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE